Psychopharmacology Overview

Principles

Definition

Psychopharmacology is an academic discipline that investigates the effects of pharmacological agents on psychological states, cognitive function, and behavior. This field examines drug mechanisms of action within the nervous system and their clinical applications in treating mental health conditions, highlighting the intricate relationship between brain chemistry and psychological processes.

Ontological type

Drug Classes

Core Mechanisms

Clinical Applications

Key developments

Key Figures

Foundations of Biological Psychopharmacology era

Arvid Carlsson [1] was a foundational figure in biological psychopharmacology during the Foundations era, with affiliations to Karolinska Institutet [3] and the University of Gothenburg [4]. His key contributions include the fluorimetric method for the determination of dopamine [7], the study of in‑vivo decarboxylation of α‑methyl DOPA and α‑methyl metatyrosine [8], and the demonstration that chlorpromazine or haloperidol can alter the formation of 3‑Methoxytyramine and normetanephrine in brain tissue [6], which together helped establish a neurochemical paradigm for psychiatric drug action in this era. Margit Lindqvist [2] was also active through the University of Gothenburg [4] and Lund University [5] during this era. Her contributions include work on the chlorpromazine/haloperidol effects on monoamine metabolism [6] and the in‑vivo decarboxylation studies of methyl‑DOPA derivatives [8], which helped illuminate how antipsychotics modulate monoamine turnover and supported the early neurochemical framework for treating severe mental illness.

Receptor-Centric Neuropharmacology era

G. Di Chiara [1] was active in the University of Brescia [3] and the University of Milan [4] during this era. His 1988 paper 'Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats' [7], the 1989 paper 'Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats' [9], and the 1995 paper 'Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the shell as compared with the core of the rat nucleus accumbens' [8] collectively anchored the receptor-centric interpretation of how drug reward maps onto mesolimbic dopamine signaling. Dennis L. Murphy [2] conducted research across Rockefeller University [5] and Stanford University [6] during this era. His 1996 paper 'Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region' [10] and his 1979 paper 'Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation' [11] advanced the integration of genetic and pharmacological biomarkers into behavioral outcomes, reinforcing biomarker-driven pharmacology in this era.

Plasticity and Rapid Therapeutics era

Dennis S. Charney [1] is a leading figure in plasticity and rapid therapeutics, with affiliations at Stanford University [3] and The University of Texas Southwestern Medical Center [4] during this era. His key contributions include the antidepressant effects of ketamine in depressed patients [7], the rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression [8], and the effects of intravenous ketamine on explicit and implicit measures of suicidality [9], collectively advancing rapid-acting therapeutics and shaping circuit- and biomarker-guided approaches. John H. Krystal [2] is a leading figure with affiliations at Harvard University [5] and University of California, San Francisco [6] during this era. His notable contributions in this era center on the ketamine antidepressant study published in 2000, 'Antidepressant effects of ketamine in depressed patients' [7], which demonstrated rapid antidepressant effects and catalyzed the field of rapid-acting therapeutics.